AOD-9604: The Growth Hormone Fragment Studied for Fat Metabolism and Joint Repair

LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.

What Is AOD-9604?

If you have spent any time researching peptides for body composition or joint health, you have likely come across AOD-9604. It tends to show up in conversations about fat metabolism, weight management, and more recently, cartilage repair. And unlike many investigational peptides, it has a documented clinical history that goes back to pharmaceutical-grade trials.

AOD-9604 is a synthetic peptide fragment derived from human growth hormone (hGH). Specifically, it corresponds to amino acids 177 through 191 of the growth hormone sequence, with a tyrosine amino acid added to stabilize it. The name stands for Anti-Obesity Drug 9604, reflecting its original development purpose.¹

What makes it scientifically interesting is its selectivity. Researchers isolated this fragment because it appeared to regulate fat metabolism the way full growth hormone does, but without triggering the broader hormonal effects that make long-term hGH use complicated. That distinction shaped both its development and its research profile.¹

Fast Facts

Full Name	Anti-Obesity Drug 9604 (AOD-9604); synthetic fragment of human growth hormone, amino acids 177-191
Class	Synthetic growth hormone fragment; lipolytic peptide
Primary Action	Stimulates fat breakdown (lipolysis) and inhibits new fat cell formation (lipogenesis) through targeted receptor binding on fat cells
Administration	Investigational; swallowed or applied in research settings
Half-Life	Approximately 30 minutes following administration2
Research	Metabolic health, weight management, osteoarthritis, and cartilage repair
Regulatory Status	Not FDA approved as a drug; classified as a GRAS food ingredient in the US; considered investigational for therapeutic use

How Does AOD-9604 Work?

Unlike complex hormones that trigger cascading reactions throughout the body, AOD-9604 operates through a highly specific mechanism focused almost entirely on fat tissue. Here is a simplified breakdown of what the research shows.

1. Targeting Fat Cells Directly

Research indicates that AOD-9604 works by mimicking the way natural growth hormone regulates fat metabolism. It binds to specific receptors on fat cells, triggering two distinct actions: it stimulates lipolysis (the breakdown of existing fat stores) and inhibits lipogenesis (the formation of new fat cells). Laboratory studies have shown that this activity is particularly pronounced in obese animal models compared to lean ones, suggesting a selective response based on metabolic state.¹

2. What It Does Not Do

The most significant aspect of how AOD-9604 works is what it does not do. Clinical studies have confirmed that unlike full human growth hormone, AOD-9604 does not increase levels of IGF-1 (Insulin-like Growth Factor 1), nor does it negatively affect carbohydrate metabolism or insulin sensitivity. This selectivity is the key reason it attracted pharmaceutical interest as a potential obesity treatment with a cleaner safety profile than hGH.²

3. Potential Role in Cartilage Repair

More recently, researchers have explored whether AOD-9604 may also influence cartilage tissue. Because growth hormone plays a role in tissue repair more broadly, scientists began testing whether this fragment retains any of that regenerative activity. Preclinical studies suggest it may stimulate chondrocytes (the cells responsible for maintaining cartilage) and reduce the activity of enzymes that break down joint tissue.³

What Does the Research Say?

AOD-9604 has a more developed clinical history than many investigational peptides, largely because it was originally developed by a pharmaceutical company and taken through formal Phase 2 trials.

RESEARCH AREA	WHAT RESEARCHERS FOUND	EVIDENCE LEVEL
Weight Management	In early clinical trials, patients taking the peptide lost an average of 2.6 kg over 12 weeks compared to 0.8 kg in the placebo group. A larger Phase 2b trial involving 536 participants over 24 weeks did not show statistically significant weight loss compared to placebo.4	Clinical Trials
Metabolic Safety	Across six randomized, double-blind human trials, researchers confirmed that the peptide did not cause insulin resistance, did not raise blood sugar levels, and did not provoke an immune system response, confirming its highly selective mechanism of action.2	Clinical Trials
Cartilage Repair	In a rabbit osteoarthritis model, intra-articular injection improved regeneration of damaged cartilage. Combining the peptide with hyaluronic acid produced even better tissue repair results than either treatment alone.3	Preclinical

Two Areas of Study

While originally developed strictly for weight loss, the research landscape for AOD-9604 has shifted over the past two decades to include regenerative medicine.

Metabolic Health

Despite mixed results in large-scale human obesity trials, researchers continue to study the peptide’s precise mechanism on fat cells. Because it was associated with fat breakdown without affecting blood sugar in research settings, scientists are investigating its potential role in broader metabolic health protocols rather than as a standalone rapid weight loss drug.¹

• Fat Breakdown: In research, AOD-9604 was associated with stimulation of lipolysis in fat cells, particularly in models with higher baseline fat levels.¹
• Metabolic Selectivity: Unlike full growth hormone, AOD-9604 was not associated with increases in IGF-1 or disruption of insulin sensitivity across multiple clinical trials.²
• Early Weight Loss Signal: In shorter-duration trials, the peptide was associated with greater weight reduction compared to placebo, though this effect was not replicated in the larger Phase 2b study.⁴

Joint and Cartilage Health

The most active modern area of study involves osteoarthritis. Because the peptide is derived from growth hormone, which plays a role in tissue repair, researchers began testing its effects on joint damage. Preclinical studies indicate that AOD-9604 may stimulate chondrocytes and reduce the activity of enzymes that break down joint tissue.³

• Cartilage Regeneration: In a rabbit osteoarthritis model, intra-articular injection of AOD-9604 was associated with improved cartilage regeneration compared to control.³
• Combination Potential: When combined with hyaluronic acid, the peptide was associated with even greater tissue repair outcomes than either agent alone in preclinical research.³

Safety Profile

AOD-9604 has a well-documented safety record for an investigational peptide. Because it was developed by a pharmaceutical company and taken through Phase 2b clinical trials, it has been evaluated in over 900 human subjects across six randomized, double-blind, placebo-controlled studies.

A comprehensive 2013 review of these trials concluded that the peptide has a tolerability profile comparable to placebo.² Researchers specifically monitored patients for the adverse effects typically associated with human growth hormone therapy, such as impaired glucose tolerance and elevated IGF-1 levels. None of these effects were observed in the trial populations studied.

Blood tests confirmed that the peptide did not trigger an immune response, meaning the body did not form antibodies against it even after 24 weeks of daily use. The most commonly reported side effects in trials were minor, including mild headaches or temporary redness at the administration site.

As with all investigational compounds, long-term safety data beyond the trial periods studied is limited, and individual responses can vary. Medical supervision is essential for anyone considering AOD-9604 as part of a therapeutic protocol.

Important Considerations

Regulatory Status: Not FDA approved as a drug as of 2026. AOD-9604 has not completed the clinical trial process required for pharmaceutical approval in the United States. It is classified as a GRAS food ingredient but is considered investigational for therapeutic use.

Evidence Strength: Strong safety data from Phase 2 trials, but mixed efficacy results for weight loss. The most robust evidence supports its metabolic selectivity, not its effectiveness as a standalone weight loss agent.

Cartilage Research Limits: Cartilage repair data is currently limited to preclinical animal studies. Human clinical trials in this area have not yet been completed, and results cannot be extrapolated directly to human outcomes.

Compounding Quality: AOD-9604 is sometimes available through compounding pharmacies. Purity and potency cannot be guaranteed without independent testing, which is one of the biggest variables in real-world use.

Not a Standalone Weight Loss Drug: The Phase 2b trial did not demonstrate statistically significant weight loss compared to placebo. AOD-9604 should not be considered a proven weight loss treatment based on current evidence.

Medical Oversight: Always work with a licensed healthcare provider before considering any investigational peptide therapy.

The Bottom Line AOD-9604 represents a focused chapter in peptide research. By isolating the fat-metabolizing fragment of human growth hormone, scientists created a targeted compound that avoids the systemic side effects of the full hormone. While it did not prove powerful enough to succeed as a standalone commercial obesity drug, its strong safety record and emerging potential in cartilage repair have kept it at the forefront of metabolic and regenerative research. The evidence is more developed than for many investigational peptides in the metabolic space, but it is not complete. Most cartilage repair data is preclinical, and the weight loss evidence is mixed. For anyone exploring AOD-9604 as part of a broader wellness or treatment conversation, the starting point should always be a conversation with a qualified healthcare provider.

Scientific References

1. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189.
2. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15.
3. Kwon DR, Park GY. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science. 2015;45(4):426-432.
4. Halford JCG. Obesity drugs in clinical development. Current Opinion in Investigational Drugs. 2006;7(4):312-318.

© 2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io.For licensing or reprint inquiries, please contact content@peptidematch.io